Skip to main content
SpringerLink
Log in

Cost Utility in Second-Line Metastatic Breast Cancer: The Authors’ Reply

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Launois R, Reboul-Marty J, Henry B, at al. A cost-utility analysis of second-line chemotherapy in metastatic cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996; 10(5): 504–21

    Article  PubMed  CAS  Google Scholar 

  2. Reboul-Marty J, Henry B, Aussage P, et al. Metastatic breast cancer management in France: a representative survey [abstract]. 12th International Conference on Pharmacoepidemiology. Amsterdam. Pharmacoepidemiol Drug Saf 1996; 5 Suppl. 1: S70

    Google Scholar 

  3. Weber B, Vogel C, Jones S. Intravenous vinorelbine as first line and second line therapy in advanced breast cancer. J Clin Oncol 1995; 13(11): 2722–30

    PubMed  CAS  Google Scholar 

  4. Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13(10): 2567–74

    PubMed  CAS  Google Scholar 

  5. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (navelbine) as a salvage treatment of advanced breast cancer. Ann Oncol 1994; 5: 423–6

    PubMed  CAS  Google Scholar 

  6. Goa K, Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 1994; 5(3): 200–34

    Article  PubMed  CAS  Google Scholar 

  7. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic review of randomized control trials in health care from the Postdam consultation on meta-analysis. J Clin Epidemiol 1995; 48(1): 161–71

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculté de Médecine de Bobigny, Université de Paris-Nord, Bobigny, France

    Robert Launois

  2. Faculté de Médecine Léonard de Vinci, Département de Santé Publique et d’Economie de la Santé, Université de Paris, Bobigny, France

    Jeanne Reboul-Marty

  3. Analyses et Recherches sur la Consommation et l’Offre de Soins, Issy-Les-Moulineaux, France

    Bernadette Henry

  4. Département d’Oncologie Medicale, Centre Oscar Lambret, Lille, France

    Jacques Bonneterre

Authors
  1. Robert Launois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeanne Reboul-Marty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernadette Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacques Bonneterre
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Launois, R., Reboul-Marty, J., Henry, B. et al. Cost Utility in Second-Line Metastatic Breast Cancer: The Authors’ Reply. PharmacoEconomics 11, 495–497 (1997). https://doi.org/10.2165/00019053-199711050-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711050-00013

Keywords

Search

Navigation